Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think we will be bought out within a year for around $20-23 per share
Wrong again!
No I agree, multiple bidders once TLD if positive. I was just stating from what we can objectively see right now is that in my opinion Merck is already in the game, and Duffy was their scout.
Exactly. NWBO had an agenda in hiring him and he had an agenda by way of Merck.
Merck buyout because:
What company in the U.S. owns the current GBM SOC, temozolomide?: MERCK
We know Dr. Duffy left MERCK, came to work for NWBO, then went back to MERCK (sounds like a scouting mission). Duffy is an experienced immunotherapy expert who lead the R&D for Keytruda. He directed Keytruda through from clinical trials to commercialization. It's naivety to think he coincidentally took a job at ,NWBO, a broke biotech company on the verge of a phase 3 trial for a therapy that will make profit in a GBM market that Merck already has its hands in.
Who stands to miss out on cornering the GBM market if DCVAX-L is efficacious and will be used along with temozolomide as new SOC?: MERCK
Money talks, and the bottom line is profit. If DCVAX-L is efficacious, I would be very surprised if MERCK did not offer to buyout at a hefty price knowing that DcVax direct is right behind DCVAX-L with the ability to treat almost all solid tumors. If MERCK owns Temozolomide and an efficacious DCVAX-L, they own the GBM market and stand to increase that bottom line (profit) greatly, along with securing the potential that direct has. It seems practical from a business sense alone that MERCK will offer a Buyout if DCVAX-L shows efficacy.
Just my opinion.
I'm hoping buyout by Merck after TLD is positive. 13-18 billion
A homerun is amazingly positive data making DCvax the new standard of care for glioblastoma. All endpoints must be met, and even better if surpassed.
No buyout because you assume to know LP's strategy? EVERYONE HAS A PRICE. Money talks....if the offer can't be refused it will not be.
Gonna get a bump today in anticipation for DL next week. .39--.40 at close. Happy Friday ya filthy animals!
Gotta love the guys on here that speak so confidently about this or that and "blah blah blah, you're all so stupid and I've got this all figured out". You are your own genius hero, not mine bro. Opinions are like A-holes and that's all you wrote...your opinion about the future.
Had a dream and saw 0.41
Maybe we will hit that by Friday close?
Or maybe I should just go back sleep
(Yawn).
GLTA!
Hmmm, let's see:
Green close so you were wrong there.
660 million shares outstanding, not 710
2020 TLD, not 2021 (you do understand this process, right?)
The shares have gone from .16 to .37 (i would say that's significant. Specifically to someone like myself who bought in cheap. So, shares are not "worthless".
What's it like being grossly wrong?
Future smells great over here!
Bahahaha. I'm currently trying to formulate a joke based on if the lock is hard or soft and taking cialis
Is that a real possibility? Within days? Do you have any evidence of this ever happening in the past? Please educate me.
You must be so much fun at parties.
Between .36--.38 on no news today.
No less than $20 per share I hope.
Opinions are like A-holes
Thank you for the time you put into this
I will refuse a coronavirus vaccine. Will you?
Because no real news yet?
If this trial fails I am financially ruined. I've sunk everything into this. 100,800 shares. Probably a lot less than many on this board. My value sits at about $36,000 plus or minus at this point? Been invested for 3 years long. Am I stupid for this leap of faith, or am I about to see a miracle? I'm swimming in about $300,000 of debt (mostly school loans, personal loans, and including mortgage. So much anxiety it has drove me to the bottle. Any insight or good advice would be appreciated. I feel like at this point with TLD on the horizon, it would be nonsensical to back out now.
Right, until you sell the transferred stock, only then will the IRS want the capital gains tax.
Can someone tell me how a partnership may effect a share price as opposed to a merger, acquisition, buyout?
Pushing .40 going into the second week of June. Data lock end of next week?
Think we will hit .40 by Friday's close?
BETHESDA, Md., June 2, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer.
The Company reported that the final data collection process has been progressing steadily despite ongoing difficulties due to coronavirus-related limitations on operations and restrictions at trial sites. The coronavirus-related difficulties have impacted most aspects of the process, including review processes at sites and even logistical matters such as the shipping of tissue slides.
The completion process includes final data collection, identification and resolution of queries, data checking and confirmation, and site sign-offs. All of these functions are performed by independent service firms (not by the Company), with oversight by the Company. The service firms have completed the final monitoring visits to the trial sites (including a number of them virtually). The service firms are in the process of resolving the queries from those final monitoring visits (each monitoring visit can generate new queries), and the firms have completed most of the data confirmations. After the query resolution and data confirmation are finished for a trial site, the site’s investigator needs to sign off on the data before it can be locked.
In light of the current status of the completion process, and the experience over recent months, the Company currently anticipates that the process may be completed by about mid-June or shortly thereafter – i.e., within a couple of weeks after the Company’s anticipated schedule at the time of the Annual Meeting in April.
If some of the information that currently remains outstanding cannot be obtained by mid-June, the Company may consider proceeding with a “soft lock” of the data at that time, if arrangements can be made for the rest of the data to be included when it is obtained later. The Company plans to obtain advice from its regulatory counsel, its Scientific Advisory Board and the Steering Committee of the trial in regard to such possibilities.
It is too early to determine what effect this update of the anticipated timing of data lock may have on the anticipated timing of the public announcement of data. There may be a similar update to the timing of the announcement of the data as to the timing of the data lock.
The steps that will take place after data lock remain the same as were outlined at the Company’s Annual Meeting. Initially following data lock, only the statisticians will be unblinded (i.e., will be given access to the database containing all of the raw data from the trial). The statisticians will need several weeks to carry out all the relevant analyses and calculations. Then the statisticians will deliver the results to the Company, and that is when the Company will become unblinded. The Company will then discuss the data with key advisors, such as its Scientific Advisory Board and the Steering Committee of the trial, and will address any comments or questions from its advisors as part of preparing the data for public announcement.
The timing of such processes cannot be predicted with precision even in normal times, and especially not in the current unprecedented circumstances. However, the Company and the independent service firms that are carrying out these processes are committed to proceeding quickly. If the anticipated timing becomes significantly different than currently anticipated, the Company plans to provide additional update bulletins.
She also said "approximately " end of May. No communication on Data Lock first week of June is acceptable by what she stated.
Speculation and opinion is not facts. The only way to know if the trial is positive or a failure is unblinding and analysis of the data. Now, that's a fact. Opinions are like A-holes, you and everyone else has one.....
In the ASM, LP said "approximately" end of May for DL. For those that do not understand the meaning of the word approximately......here it is:
"used to show that something is almost, but not completely, accurate or exact; roughly."
What information is available? Please enlighten us?
Probably not much movement on mediocre volume. Will stick between .29 and .34 on zero news. If they announce data lock then of course we will see a bump with a steady rise to $1.00 by TLD in mid to late summer. If TLD is positive, then who knows what possibilities await the share price, but I'm thinking buyout from Merck that will give share holders anywhere between $18-32 per share. Just my opinion....really meaningless in the grand scope.
"After factoring in the March and April shutdowns, and the additional genetic analysis, the Company believes it can reach data lock by approximately the end of May.
Upon reaching data lock, the data will be unblinded to the independent statisticians (i.e., the statisticians will be given access to the trial database containing all of the raw data points). The Company will not yet become unblinded at this time.
The independent statisticians will then use the raw data to calculate the relevant measures, such as median survival times and survival percentages at various time points. The statisticians will also calculate various statistical measures and prepare graphs and tables. This work is anticipated to take several weeks. The Company will become unblinded when it receives these results from the statisticians.
The Company will then discuss the information from the statisticians with its expert advisors, including its Scientific Advisory Board and the Steering Committee of the Phase 3 trial. Any questions or comments raised by the experts will be addressed and the results will be prepared for public announcement.
Based on these expectations, and taking account of the two months lost in March and April, the current estimate of public disclosure of top line data would range from the end of June to early"
I was there for the ASM, and I agree with you.
With the trend starting from last week, we should be in line to reach .40 by close today. The rise may start to slow or even stagnate and fall if no data lock is announced before today or end of May. Linda said should reach data lock approximately by end of May. People (,specifically those looking to jump on a bandwagon, or make quick money) are banking on that to happen. Us longs....well...we still patiently await results no matter how long it takes....why would we back out now? Godspeed fellow longs! It's been quite a journey.
Wasn't that her agenda all along?
Kite and Juno are good benchmarks....I'm guessing BO from 15bn-25bn. Let's hope for a grand slam
What company in the U.S. owns the current GBM SOC, temozolomide?: MERCK
We know Dr. Duffy left MERCK, came to work for NWBO, then went back to MERCK (sounds like a scouting mission). Duffy is an experienced immunotherapy expert who lead the R&D for Keytruda. He directed Keytruda through from clinical trials to commercialization. It's naivety to think he coincidentally took a job at ,NWBO, a broke biotech company on the verge of a phase 3 trial for a therapy that will make profit in a GBM market that Merck already has its hands in.
Who stands to miss out on cornering the GBM market if DCVAX-L is efficacious and will be used along with temozolomide as new SOC?: MERCK
Money talks, and the bottom line is profit. If DCVAX-L is efficacious, I would be very surprised if MERCK did not offer to buyout at a hefty price knowing that DcVax direct is right behind DCVAX-L with the ability to treat almost all solid tumors. If MERCK owns Temozolomide and an efficacious DCVAX-L, they own the GBM market and stand to increase that bottom line (profit) greatly, along with securing the potential that direct has. It seems practical from a business sense alone that MERCK will offer a Buyout if DCVAX-L shows efficacy.
Just my opinion.
Let's here some timeline, pps, or buyout theories if TLD is positive. I wanna know what everyone's hope and aspirations are for their investment as this long awaited trial starts coming to a close. What are your opinions?